Shares Outstanding Shares Outstanding n/a Close	26.83M
Shares Change (YoY) Shares Change (YoY) n/a Close	n/a
Shares Change (QoQ) Shares Change (QoQ) n/a Close	n/a
Owned by Institutions (%) Owned by Institutions (%) n/a Close	13.29%
Shares Floating Shares Floating n/a Close	n/a
Failed to Deliver (FTD) Shares Failed to Deliver (FTD) Shares n/a Close	1,823
FTD / Avg. Volume FTD / Avg. Volume n/a Close	0.01%

Short Selling Information

The latest short interest is 129.16K, so 0.48% of the outstanding shares have been sold short.

Short Interest Short Interest n/a Close	129.16K
Short % of Shares Out Short % of Shares Out n/a Close	0.48%
Short % of Float Short % of Float n/a Close	0.52%
Short Ratio (days to cover) Short Ratio (days to cover) n/a Close	1

Valuation Ratios

The PE ratio is -1.34 and the forward PE ratio is -0.04. Syros Pharmaceuticals's PEG ratio is -0.03.

PE Ratio PE Ratio n/a Close	-1.34
Forward PE Forward PE n/a Close	-0.04
PS Ratio PS Ratio n/a Close	22.21
Forward PS Forward PS n/a Close	0.4
PB Ratio PB Ratio n/a Close	13.24
P/FCF Ratio P/FCF Ratio n/a Close	-2.01
PEG Ratio PEG Ratio n/a Close	-0.03

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Syros Pharmaceuticals.

EV / Sales EV / Sales n/a Close	n/a
EV / EBITDA EV / EBITDA n/a Close	n/a
EV / EBIT EV / EBIT n/a Close	n/a
EV / FCF EV / FCF n/a Close	n/a

Financial Position

The company has a current ratio of 3.95, with a Debt / Equity ratio of 3.73.

Current Ratio Current Ratio n/a Close	3.95
Quick Ratio Quick Ratio n/a Close	3.95
Debt / Equity Debt / Equity n/a Close	3.73
Debt / EBITDA Debt / EBITDA n/a Close	-0.39
Debt / FCF Debt / FCF n/a Close	-0.56
Interest Coverage Interest Coverage n/a Close	-25.16

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity Return on Equity n/a Close	n/a
Return on Assets Return on Assets n/a Close	n/a
Return on Invested Capital Return on Invested Capital n/a Close	n/a
Revenue Per Employee Revenue Per Employee n/a Close	$146,117.65
Profits Per Employee Profits Per Employee n/a Close	$-2,420,205.88
Employee Count Employee Count n/a Close	68
Asset Turnover Asset Turnover n/a Close	0.06
Inventory Turnover Inventory Turnover n/a Close	n/a

Taxes

Income Tax Income Tax n/a Close	n/a
Effective Tax Rate Effective Tax Rate n/a Close	0%

Stock Price Statistics

The stock price has increased by -99.43% in the last 52 weeks. The beta is 1.56, so Syros Pharmaceuticals's price volatility has been higher than the market average.

Beta Beta n/a Close	1.56
52-Week Price Change 52-Week Price Change n/a Close	-99.43%
50-Day Moving Average 50-Day Moving Average n/a Close	0.03
200-Day Moving Average 200-Day Moving Average n/a Close	0.7
Relative Strength Index (RSI) Relative Strength Index (RSI) n/a Close	40.75
Average Volume (20 Days) Average Volume (20 Days) n/a Close	20,659,115

Income Statement

In the last 12 months, Syros Pharmaceuticals had revenue of 9.94M and earned -164.57M in profits. Earnings per share was -5.81.

Revenue Revenue n/a Close	9.94M
Gross Profit Gross Profit n/a Close	7.68M
Operating Income Operating Income n/a Close	-128.99M
Net Income Net Income n/a Close	-164.57M
EBITDA EBITDA n/a Close	-157.19M
EBIT EBIT n/a Close	-159.45M
Earnings Per Share (EPS) Earnings Per Share (EPS) n/a Close	-5.81

Full Income Statement

Balance Sheet

The company has 139.53M in cash and 62.08M in debt, giving a net cash position of 77.45M.

Cash & Cash Equivalents Cash & Cash Equivalents n/a Close	139.53M
Total Debt Total Debt n/a Close	62.08M
Net Cash Net Cash n/a Close	77.45M
Retained Earnings Retained Earnings n/a Close	-722.81M
Total Assets Total Assets n/a Close	85M
Working Capital Working Capital n/a Close	35.54M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -109.71M and capital expenditures -272K, giving a free cash flow of -109.98M.

Operating Cash Flow Operating Cash Flow n/a Close	-109.71M
Capital Expenditures Capital Expenditures n/a Close	-272K
Free Cash Flow Free Cash Flow n/a Close	-109.98M
FCF Per Share FCF Per Share n/a Close	-3.88

Full Cash Flow Statement

Margins

Gross margin is 77.33%, with operating and profit margins of -1298.19% and -1656.34%.

Gross Margin Gross Margin n/a Close	77.33%
Operating Margin Operating Margin n/a Close	-1298.19%
Pretax Margin Pretax Margin n/a Close	-1656.34%
Profit Margin Profit Margin n/a Close	-1656.34%
EBITDA Margin EBITDA Margin n/a Close	-1582.08%
EBIT Margin EBIT Margin n/a Close	-1298.19%
FCF Margin FCF Margin n/a Close	-1106.87%

Dividends & Yields

SYRS does not appear to pay any dividends at this time.

Dividend Per Share Dividend Per Share n/a Close	n/a
Dividend Yield Dividend Yield n/a Close	n/a
Dividend Growth (YoY) Dividend Growth (YoY) n/a Close	n/a
Payout Ratio Payout Ratio n/a Close	n/a
Earnings Yield Earnings Yield n/a Close	n/a
FCF Yield FCF Yield n/a Close	n/a

Dividend Details

Analyst Forecast

The average price target for SYRS is $3, which is 9900% higher than the current price. The consensus rating is "Hold".

Price Target Price Target n/a Close	$3
Price Target Difference Price Target Difference n/a Close	9900%
Analyst Consensus Analyst Consensus n/a Close	Hold
Analyst Count Analyst Count n/a Close	5

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value Lynch Fair Value n/a Close	n/a
Lynch Upside Lynch Upside n/a Close	n/a
Graham Number Graham Number n/a Close	n/a
Graham Upside Graham Upside n/a Close	n/a

Stock Splits

The last stock split was on Sep 19, 2022. It was a backward split with a ratio of 1:10.

Last Split Date Last Split Date n/a Close	Sep 19, 2022
Split Type Split Type n/a Close	backward
Split Ratio Split Ratio n/a Close	1:10

Scores

Altman Z-Score Altman Z-Score n/a Close	-15.54
Piotroski F-Score Piotroski F-Score n/a Close	0